Laboratory

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Retrieved on: 
Friday, March 22, 2024
B cell, Conference, Longevity, National University Health System, TELO, The New York Times, BGCT, Health, Chromosome, Research, DNA, EDT, Laboratory, MD, Skin, Poster, Telomere, Osteoarthritis, Blood, NUHS, Ageing, Pharmaceutical industry

BALTIMORE, March 22, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and Danielle R. Baker, Ph.D., of Frontage Laboratories will present a scientific poster presentation at the Global Longevity Federation Conference in Las Vegas on March 26th at 2 pm EDT. The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.

Key Points: 
  • The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.
  • This presentation builds on the data that was presented at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 in February.
  • “Presenting our poster at the Global Longevity Federation conference offers a significant opportunity for our team to showcase the potential for Telomir-1.
  • To be added to the Telomir Pharmaceuticals email distribution list, please email [email protected] with TELO in the subject line.

Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in India

Retrieved on: 
Friday, March 22, 2024
Cardiac output, U.S. FDA, Internal bleeding, Partnership, System, Patient, Research, Trauma, Diarrhea, Hypovolemic shock, Mortality, Gastrointestinal bleeding, Manuscript, Laboratory, Blood volume, Standard of care, DRUGS, Clinical trial, Resuscitation, Safety, DCGI, Phase, Vomiting, Blood, FDA, Food, Shock (mechanics), Emerging market, Generic drug

Developed by Pharmazz for potential global use, Centhaquine is a resuscitative agent presently indicated for treating hypovolemic shock by Drugs Controller General of India (DCGI).

Key Points: 
  • Developed by Pharmazz for potential global use, Centhaquine is a resuscitative agent presently indicated for treating hypovolemic shock by Drugs Controller General of India (DCGI).
  • As per the agreement, Dr. Reddy's has received exclusive rights to market and distribute Centhaquine in India.
  • For patients with hypovolemic shock, I believe Dr. Reddy's is the best partner for Pharmazz to market Centhaquine, an innovative, first-in-class novel resuscitative agent, in India."
  • U.S. FDA clearance of our Phase III IND is an important milestone for Pharmazz and the potential future treatment of hypovolemic shock patients.

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

Retrieved on: 
Wednesday, March 20, 2024
Sepsis, Development, Lyme disease, Growth, Panel, International, Laboratory, Instrument, LDT, ASPR, Journal of Clinical Microbiology, Pharmaceutical industry

LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.

Key Points: 
  • LEXINGTON, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.
  • The Company is currently in discussions with potential LDT partners and plans to provide early Lyme disease results to U.S. reference laboratories nationwide.
  • Engaged Dr. Robin Robinson as a strategic advisor to aid in commercialization of the T2Biothreat Panel.
  • A live and recorded webcast of the call will be available on the “Investors” section of the Company’s website at www.t2biosystems.com .

Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes

Retrieved on: 
Wednesday, March 20, 2024
DPT, CDMO, Growth, Chairperson, Wynnefield Capital, University, Laboratory, Head, Senior, Marketing, Syringe, Investment, Annual report, Retirement, Calendar, Corporate development, Fiscal, Management

CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that its Board of Directors unanimously approved the conclusion of its review of strategic alternatives that was initiated in March 2023, and, concurrently therewith, announced several strategic updates related to its operations on a stand-alone basis.

Key Points: 
  • This conclusion was based on an expansive strategic review process, including outreach to and engagement with over 75 buyers, including both strategic buyers and financial sponsors.
  • “The Board of Directors appreciates all of the hard work put into the strategic review process by the Company and its advisors.
  • The Board looks forward to working with the management team to lead the Company’s execution on its strategic plan,” said Craig Barbarosh, Chairman of the Board.
  • With these investments, Lifecore believes it is positioned for substantial growth as its additional aseptic capacity becomes available.

Impressive $3.3M investment in Basic Mental Health Research

Retrieved on: 
Tuesday, March 19, 2024
Depression, Health, Basics, Mental health, Obesity, Prevalence, Drug discovery, University of Calgary, Insulin, Risk, Knowledge, Insulin resistance, The Honourable, Power Corporation of Canada, Research, Anxiety, University, Laboratory, Health Canada, Woman, Addiction, University of Toronto, Nursing

Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.

Key Points: 
  • Basic research is scientific research carried out primarily to expand knowledge and understanding rather than to directly address clinical or practical issues.
  • The Basics of Better Mental Health Program funds basic research that will provide insight into the causes and onset of mental health conditions, explore the neuropathological changes and information-processing deficits that may eventually lead to new directions for treatments and interventions, and explore the role of sex and gender in mental health.
  • "Brain research plays a critical role in increasing our understanding of the causes and onset of mental health conditions,” says the Honourable Ya’ara Saks, Minister of Mental Health and Addictions.
  • “I am thrilled to support the work being done through the Basics of Better Mental Health Program – this work will support better mental health for all Canadians.”
    “The inclusion of sex-specific biological considerations is instrumental in understanding the biological roots of mental health conditions,” says Dr. Viviane Poupon, President and CEO of Brain Canada.

QDx Pathology Services Adopts Proscia’s Software To Improve Speed And Precision

Retrieved on: 
Tuesday, March 19, 2024
Culture, AP, Organization, Digital, Artificial intelligence, News, Marie Cassidy, AI, Software, Laboratory, USCAP, FDA, Medical imaging

Accelerated by a growing base of evidence, laboratories are adopting digital pathology to enhance routine operations, improve decision making, and lay the foundation for unlocking new insights with AI.

Key Points: 
  • Accelerated by a growing base of evidence, laboratories are adopting digital pathology to enhance routine operations, improve decision making, and lay the foundation for unlocking new insights with AI.
  • “At QDx Pathology Services, we are committed to advancing the standard of excellence in pathology,” said Pierre Mouawad, VP of Laboratory Operations.
  • “Proscia’s software makes it easier for our pathologists to do their best work, empowering them to optimize for speed and precision.
  • “It is inspiring to watch QDx Pathology Services take the first steps on its digital pathology journey,” said David West, Proscia’s CEO.

Azimut and SOQUEM Resume Drilling on the High-Grade Lithium Zone at Galinée, James Bay Region, Quebec

Retrieved on: 
Monday, March 18, 2024
Diamond, Cree, ALS, ICP, Laboratory, Winsome, Lithium, BTW, Azimut

A minimum 2,500-metre drilling phase aims to further define and expand the high-grade lithium zone discovered during the maiden program in late 2023.

Key Points: 
  • A minimum 2,500-metre drilling phase aims to further define and expand the high-grade lithium zone discovered during the maiden program in late 2023.
  • Azimut and its partner SOQUEM Inc. have ranked the Galinée Property as one of their top priorities for 2024.
  • As currently defined, the lithium zone on Galinée has a strike length of 700 metres and trends roughly east-west.
  • Miikan Drilling is owned by local communities and Chibougamau Diamond Drilling Ltd of Chibougamau (Quebec).

Pharming Group reports fourth quarter and full year 2023 financial results

Retrieved on: 
Thursday, March 14, 2024
Patient, Health care, Epidemiology, Executive Committee, Laboratory, Microsoft Access, Lymphocyte, Clinical trial, European Commission, APDS, MHLW, AEG, Welfare, Ageing, Committee, EMA, Trial of the century, PID, CTLA4, Safety, Pharmacokinetics, Ministry, CHMP, ODD, U.S. FDA, Prevalence, PTEN, Disease, HAE, Immunodeficiency, VUS, Literature, PIK3R1, PMDA, FDA, DSM-IV codes, Diagnosis, Civil service commission, IRP, Haploinsufficiency, Genetic testing, MAA, Autoimmunity, World Games, Iberian languages, Marketing, MHRA, Euronext Amsterdam, PIK3CD, Physician, Pharmaceutical industry

The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.

Key Points: 
  • The U.S. market contributed 97% of 2023 revenues, while the EU and Rest of World contributed 3%.
  • Revenues increased to US$7.9 million in the fourth quarter of 2023, driven by the continued increase in patients on paid therapy, and revenues were US$18.2 million for 2023.
  • Pharming made continued progress in the fourth quarter of 2023 on leniolisib regulatory filings for APDS patients 12 years of age and older in key global markets.
  • Pharming filed regulatory submissions in Canada and Australia in the third quarter of 2023, and Israel in the second quarter.

MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts

Retrieved on: 
Wednesday, March 13, 2024
Patient, Child, Laboratory, Duchenne muscular dystrophy, University of Oxford, School, Research, Inflammation, Electrophysiology, National Science Foundation, Immunology, Rockefeller University, Research fellow, Neuromuscular disease, Pediatrics, Pathology, SAB, IRB, CNRS, Neurology, Inflammation Research, Surgery, University, Neuro, MD, Senior, Consultant, Chemokine, Medical school, Retirement, CSO, Myopathy, Signal transduction, Doctor of Philosophy, Nursing

Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).

Key Points: 
  • Ferdinando Nicoletti, MD, PhD, has been Full Professor of General Pathology and Immunology since 2011 at the University of Catania (Italy).
  • “We welcome the members of MetrioPharm’s newly established scientific advisory board,” said Thomas Christély, CEO of MetrioPharm.
  • “We are happy to now formally establish and introduce this panel of experts for an even closer collaboration.
  • Every aspect of our research development program - from preclinical research to clinical trials - will benefit from the unparalleled expertise of our new scientific advisors.”

Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
University of Illinois Urbana-Champaign, Drug discovery, Schering-Plough, Patient, Genentech, Acquisition, Cancer, Laboratory, Biology, Northern Illinois University, Stanford University, Amgen, Pharmaceutical industry

CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced the appointment of Thomas J. Schall, Ph.D., former Chairman, CEO and Founder of ChemoCentryx before its acquisition by Amgen, to its Board of Directors.
  • “On behalf of the entire Immuneering team, we are honored to welcome Dr. Schall to our Board,” said Ben Zeskind, Chief Executive Officer, Immuneering Corporation.
  • From 1993 to 1997, Dr. Schall worked at the DNAX Research Institute, a division of Schering-Plough Corporation.
  • in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University.